Vantia Therapeutics appoints new chief executive
Andrew Crockett wins promotion after 12 months with pharma company
Since joining the Southampton, UK-based emerging pharmaceutical firm in 2009 as vice president of business development, Crockett has made a significant contribution to Vantia’s corporate development. He was previously with US specialist pharma company ZARS Pharma.
Martin Murphy, non-executive chairman of Vantia, said: ‘We are very pleased that Andrew Crockett has accepted the position as ceo. Vantia has made considerable progress over the past two years in advancing its pipeline of novel small molecule drug candidates into Phase II clinical trials. We wish Jim Phillips, the former ceo, well and appreciate his contribution to the team. The management team has created a solid platform for Vantia and we are therefore very pleased that Andrew will continue the great work that has been started.’
Crockett added: ‘We are looking forward to an exciting second half of the year when we expect important clinical data from our Phase IIa efficacy study in dysmenorrhoea and from our Phase IIb study in nocturia.’
Vantia Therapeutics develops novel, small molecule drugs targeting large, underserved medical markets. Formed in 2008 as a spin-out of Ferring Research’s small molecule r&d, it has two clinical phase products, VA106483 for the treatment of nocturia and VA111913 for the treatment of dysmenorrhoea, as well as preclinical and discovery programmes based on protease inhibition with potential in the areas of oncology and inflammation.
You may also like
Research & Development
Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform
Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Research & Development
Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption
A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Manufacturing
Degasser for volatile and aggressive solvents
Biotech Fluidics announce the DEGASi Integration HFIP - a high-performance online system designed to efficiently degas even the toughest solvents. This unique degasser is fully compatible with a wide range of volatile and aggressive liquids including Hexafluoroisopropanol (HFIP) and silanes but can also manage all other solvents used for GPC/SEC and HPLC
Research & Development
Symeres joins forces with Ambagon Therapeutics to expand molecular glue research in colorectal cancer
The pair will aim to explore a new class of small molecules, known as molecular glues, for potential therapeutic use in colorectal cancer and other hard-to-target diseases as an alternative to traditional therapies
Research & Development
University of Exeter leads £4.5m Wellcome-funded initiative to develop bioimaging tools for fungal pathogens
An international collaboration spanning the universities of Exeter, Edinburgh and Cape Town has secured £4.5m to develop specialist bioimaging tools for WHO-priority fungal pathogens